Dr. Oz’s Pharma, Medicare Views to Influence US Drug Price Talks

Mehmet Oz, both a big pharma critic and investor, will get to put his mark on the Biden administration’s signature drug price negotiation program if confirmed to lead the Centers for Medicare & Medicaid Services under President-elect Donald Trump.

Trump’s selection of Oz to lead the Medicare agency would allow the surgeon-turned-TV personality to oversee the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

President Joe Biden‘s key legislative achievement, passed in 2022, gives the US powerful authority to negotiate with the pharmaceutical industry over the costs for some of the most widely used and expensive medicines covered by ...